Cargando…
Novel Experimental Agents for the Treatment of Hypercholesterolemia
Atherosclerotic cardiovascular diseases (ASCVD) are still the leading cause of morbidity and mortality in most developed countries and even more in developing countries. Dyslipidemia is a well known main risk factor for ASCVD. Lipid-lowering treatment, particularly lowering LDL-cholesterol (LDL-C),...
Autores principales: | Pećin, Ivan, Reiner, Željko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887150/ https://www.ncbi.nlm.nih.gov/pubmed/33603500 http://dx.doi.org/10.2147/JEP.S267376 |
Ejemplares similares
-
Present and Future of Dyslipidaemia Treatment—A Review
por: Merćep, Iveta, et al.
Publicado: (2023) -
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
por: Pećin, Ivan, et al.
Publicado: (2017) -
Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia
por: Kosmas, Constantine E., et al.
Publicado: (2018) -
Drug Treatment of Hypercholesterolemia in Older Adults: Focus on Newer Agents
por: Stoll, Felicitas, et al.
Publicado: (2022) -
Novel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future Challenges
por: Jiang, Long, et al.
Publicado: (2018)